Synopsis
Hendra virus infection of horses occurred sporadically between 1994 and 2010 as a result of spill-over from the viral reservoir in Australian mainland flying-foxes, and occasional onward transmission to people also followed from exposure to affected horses. For reasons that are not well understood an unprecedented number of outbreaks were recorded in 2011, including the first recorded field infection of a dog, leading to heightened community concern. Increasingly, pressure mounted to instigate measures for control of flying-fox numbers, and equine health care workers started to leave the industry on account of risk and liability concerns. Release of an inactivated subunit vaccine for horses against Hendra virus represents the first commercially available product that is focused on mitigating the impact of a Biosafety Level 4 pathogen. Through preventing the development of acute Hendra virus disease in horses, vaccine use is also expected to reduce the risk of transmission of infection to people. This approach to emerging infectious disease management focuses on the role of horses as the proximal cause of human Hendra virus disease, and may assist in redirecting community concerns away from the flying-fox reservoirs, keystone species for the ongoing health of Australia’s native forests.